CF
Therapeutic Areas
Regeneron Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EYLEA (aflibercept) | Wet AMD, diabetic macular edema, retinal vein occlusion | Approved |
| Dupixent (dupilumab) | Atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis | Approved |
| Libtayo (cemiplimab) | Cutaneous squamous cell carcinoma, basal cell carcinoma, NSCLC | Approved |
| Praluent (alirocumab) | High cholesterol | Approved |
| Kevzara (sarilumab) | Rheumatoid arthritis | Approved |
| Evkeeza (evinacumab) | Homozygous familial hypercholesterolemia | Approved |
| EYLEA HD | Wet AMD, diabetic macular edema | Phase 3 |
| Dupixent | COPD | Phase 3 |
Leadership Team at Regeneron Pharmaceuticals
LS
Leonard Schleifer
Co-Founder, President and Chief Executive Officer
GY
George Yancopoulos
Co-Founder, President and Chief Scientific Officer
RL
Robert Landry
Executive Vice President and Chief Financial Officer
MM
Marion McCourt
Executive Vice President, Commercial
IL
Israel Lowy
Executive Vice President, Chief Medical Officer
DV
Daniel Van Plew
Executive Vice President, General Counsel
RC
Ryan Crowe
Executive Vice President, Chief Business Officer